Gilead Sciences Inc (GILD)vsNational Grid PLC ADR (NGG)
GILD
Gilead Sciences Inc
$129.16
-0.22%
HEALTHCARE · Cap: $158.39B
NGG
National Grid PLC ADR
$81.86
+0.39%
UTILITIES · Cap: $80.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Gilead Sciences Inc generates 68% more annual revenue ($29.74B vs $17.69B). GILD leads profitability with a 31.0% profit margin vs 18.3%. NGG appears more attractively valued with a PEG of 1.00. GILD earns a higher WallStSmart Score of 68/100 (B-).
GILD
Strong Buy68
out of 100
Grade: B-
NGG
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+41.6%
Fair Value
$221.22
Current Price
$129.16
$92.06 discount
Intrinsic value data unavailable for NGG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 39.3%
Earnings expanding 54.8% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Strong operational efficiency at 32.6%
Large-cap with strong market position
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
4.4% revenue growth
Grey zone — moderate risk
Trading at 8.2x book value
2.0% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GILD
The strongest argument for GILD centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.0% and operating margin at 39.3%.
Bull Case : NGG
The strongest argument for NGG centers on Operating Margin, Market Cap, PEG Ratio. Profitability is solid with margins at 18.3% and operating margin at 32.6%. PEG of 1.00 suggests the stock is reasonably priced for its growth.
Bear Case : GILD
The primary concerns for GILD are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : NGG
The primary concerns for NGG are Price/Book, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
NGG carries more volatility with a beta of 0.62 — expect wider price swings.
GILD is growing revenue faster at 4.4% — sustainability is the question.
GILD generates stronger free cash flow (2.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GILD scores higher overall (68/100 vs 62/100), backed by strong 31.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gilead Sciences Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
National Grid PLC ADR
UTILITIES · UTILITIES - REGULATED ELECTRIC · USA
National Grid plc transmits and distributes electricity and natural gas. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?